argenx

Showing 2 posts of 2 posts found.

argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment

February 20, 2024
Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA

argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …

abbvie_0

Abbvie acquires immune-oncology target from argenx

April 21, 2016
Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive

AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …

The Gateway to Local Adoption Series

Latest content